30 years of historical data (1995–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
CAMP4 Therapeutics Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $210M | $102M | — | — | — | — | — | — | — | — | — |
| Enterprise Value | $155M | $46M | — | — | — | — | — | — | — | — | — |
| P/E Ratio → | -1.69 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 322.84 | 156.16 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.39 | 1.61 | — | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 71.21 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
CAMP4 Therapeutics Corporation earns an operating margin of -8142.3%. Operating margins have expanded from -14822.6% to -8142.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -82.0% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 41.2% | 39.7% | 39.1% | 40.6% | 41.2% | 40.8% | 36.7% |
| Operating Margin | -8142.3% | -8142.3% | -14822.6% | — | -5.2% | -1.3% | -4.6% | 5.4% | 2.2% | 0.4% | 10.0% |
| Net Profit Margin | -7943.4% | -7943.4% | -14083.1% | — | -10.5% | -6.9% | -21.5% | 5.1% | 4.5% | -2.0% | 6.0% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -82.0% | -82.0% | — | -3335.2% | -34.7% | -17.8% | -45.9% | 9.1% | 9.2% | -4.0% | 9.9% |
| ROA | -77.7% | -77.7% | -62.6% | -17.5% | -7.4% | -4.5% | -14.3% | 3.4% | 3.8% | -1.8% | 5.8% |
| ROIC | — | — | — | -135.2% | -5.5% | -1.2% | -5.1% | 6.6% | 2.7% | 0.5% | 13.7% |
| ROCE | -91.7% | -91.7% | -73.2% | -22.4% | -4.8% | -1.1% | -3.8% | 4.4% | 2.2% | 0.4% | 11.5% |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $64M exceeds total debt of $9M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.14 | — | — | 2.61 | 2.12 | 1.70 | 1.34 | 0.78 | 0.90 | 0.74 |
| Debt / EBITDA | — | — | — | — | 27.92 | 11.63 | 15.41 | 6.95 | 4.99 | 5.92 | 3.65 |
| Net Debt / Equity | — | -0.88 | — | — | 1.47 | 1.20 | 0.92 | 0.09 | 0.11 | 0.32 | 0.00 |
| Net Debt / EBITDA | — | — | — | — | 15.76 | 6.57 | 8.35 | 0.49 | 0.70 | 2.14 | 0.01 |
| Debt / FCF | — | — | — | — | — | 6.91 | — | 0.54 | 0.37 | 2.98 | 0.01 |
| Interest Coverage | — | — | — | -7.19 | -1.00 | -0.25 | -0.83 | 1.18 | 0.77 | 0.14 | 3.70 |
Net cash position: cash ($64M) exceeds total debt ($9M)
Short-term solvency ratios and asset-utilisation metrics
CAMP4 Therapeutics Corporation's current ratio of 6.92x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 10.62x to 6.92x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.92 | 6.92 | 5.13 | 10.62 | 2.04 | 2.00 | 1.96 | 4.83 | 2.89 | 2.70 | 6.03 |
| Quick Ratio | 6.92 | 6.92 | 5.13 | 10.62 | 1.83 | 1.70 | 1.66 | 4.44 | 2.51 | 2.32 | 5.69 |
| Cash Ratio | 6.67 | 6.67 | 4.92 | 10.47 | 0.96 | 0.85 | 0.88 | 3.28 | 1.63 | 1.31 | 4.60 |
| Asset Turnover | — | 0.01 | 0.01 | — | 0.74 | 0.70 | 0.74 | 0.60 | 0.77 | 0.86 | 0.73 |
| Inventory Turnover | 8.62 | — | — | — | 8.62 | 5.79 | 6.06 | 6.74 | 5.92 | 7.10 | 10.62 |
| Days Sales Outstanding | — | 60.46 | 460.94 | — | 72.29 | 80.26 | 72.05 | 78.34 | 71.40 | 70.07 | 64.27 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
CAMP4 Therapeutics Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $20M | $12M | $36M | $35M | $34M | $34M | $35M | $36M | $36M | $37M |
Compare CAMP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| CAMPYou | $210M | -1.7 | — | — | 100.0% | -8142.3% | -82.0% | — | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| RNA | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CAMP stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonCAMP4 Therapeutics Corporation's current P/E ratio is -1.7x. This places it at the 50th percentile of its historical range.
CAMP4 Therapeutics Corporation's return on equity (ROE) is -82.0%. The historical average is -8.7%.
Based on historical data, CAMP4 Therapeutics Corporation is trading at a P/E of -1.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
CAMP4 Therapeutics Corporation has 100.0% gross margin and -8142.3% operating margin.